Best Life Sciences Companies in Albuquerque, United States

Provider of RNA-based diagnostics and therapeutics to treat depression. The company has developed a circular RNA-based genomic assay as a biomarker that provides a therapeutic response for individuals with psychiatric and neurological conditions.

VisionQuest Biomedical develops diagnostic devices for ophthalmic diseases and diabetic complications. Its platform technology EyeStar is an imaging software that is used for the automated diagnosis of diabetic retinopathy, and is compatible with existing retinal cameras. Another software ASPIRE is used in conjunction with existing retinal cameras for the diagnosis of malarial retinopathy. VisionQuest is also developing a device for the early diagnosis of diabetic neuropathy.

Developer of long-read DNA sequencing technology for precision medicine. The technology used is a nanopore-based sequencing technique for enabling the detection of genome variations. It enables clinicians to provide precision medicine.

{}

Funding rounds

• Sep 2024Grant (prize money)$295.3K
• Feb 2016Grant (prize money)$2.1M
• Jul 2014Grant (prize money)$150K

Founders & team

Alexander UkhanovOwner

Investors

OSTI

Tech stack

WordpressMysqlPhpGoogle MapsHello ElementorElementor

Pioneering respiratory patient care through innovative inhalation medicine technologies. This company focuses on re-envisioning inhalation medicines and their delivery to the lungs, aiming to transform the treatment of high-dose lung delivery. They are developing new technologies and therapies for lung-related diseases that are currently difficult to treat. Their mission is centered around improving patients' lives through advancements in respiratory care. They are committed to delivering results, acting pragmatically, moving fast, fostering trust and support, and doing the right thing. This is a B2B tech company focused on medical devices and respiratory therapies.

Provider of sampling, detection, and identification products. The flagship products of the company are fieldable aerosol mass spectrometers and complementary products for protection from biological and low-volatility chemical threats. Also, it develops Handheld Air Sampler for SARS-CoV-2 detection.

Provider of flow cytometry equipment and services. The company's product is "Velocyt" a 3D multicellular model system that delivers breakthrough technological innovation in flow cytometry for cancer research and drug development. Additionally, it also developing new products for rare cell sorting and the generation of 3D tissue models for disease research.

Developer of a non-pharmacologic treatment for cerebrovascular disease. This treatment offers a new approach to managing cerebrovascular disease, applicable in pre-hospital settings and expanding treatment options for patients. It can be used in individuals ineligible for traditional therapies and may reduce the risk of recurrent stroke. The company is focused on obtaining regulatory approvals and commercializing this innovative therapy through clinical trials.

Funding rounds

• Sep 2024Grant (prize money)$490K

Founders & team

Edwin NemotoFounder & CEO

Investors

HHS

Exhalix is developing a non-invasive technique for monitoring endothelial dysfunction, the underlying cause of PAD and other vascular circulation issues. The company uses an electrocatalytic sensing technique with sampling methods to non-intrusively measure the biomarkers that are indications of different disorders. As of October 2017, the company is developing both office-based and miniaturized home-based sensing technologies. The company's method of electrocatalysis is based on metalized Nafion or solid polymer electrolyte membranes; The nanoporous metallic electrocatalyst is in direct contact with the gas phase molecules which do not have to diffuse through a membrane to react on the sensing surface as is the case in Clark-type sensors.

Funding rounds

• Aug 2022Grant (prize money)$300.4K
• Sep 2021Grant (prize money)$2.3M
• Feb 2020Grant (prize money)$298.3K
• Jul 2016Grant (prize money)$270K

Founders & team

Reza ShekarrizFounder & Director

Investors

HHS

nanoMR has developed the system for rapid isolation of rare cells from complex matrices at levels of 1 cell/mL or lower. The immunomagnetic capture system can target multiple cell types simultaneously, for example capturing bacteria and fungi from bloodstream infections, or specific cell types, such as circulating tumor, or fetal, cells, in less than 30 minutes.

Biomarker screening for diabetes detection

Founders & team

Christopher MoreauPresident & CEO

Investors

Psilos Group, Wasatch Advisors, Dow Chemical Company, Signal Peak

Life science company providing innovative solutions for research and biopharmaceutical manufacturing. The company offers a wide array of products and services, including high-throughput screening by cytometry instruments, software, reagents, and support. These solutions accelerate antibody discovery, T-cell engineering, and immuno-oncology research. The company ensures compliance with legal regulations through its compliance management system, codes of conduct, and incident reporting mechanisms. It provides tools for cell analysis, live cell analysis, lab filtration, purification, microbiological testing, and protein analysis. The company is committed to ethical conduct, human rights, and environmental protection, reflected in its codes of conduct for employees and business partners. The company fosters a speak-up culture, encouraging transparent communication and providing channels for reporting potential violations. The company's offerings cater to the biopharmaceutical industry, research institutions, and laboratories, supporting advancements in life sciences and healthcare.